Difference between revisions of "Papillary renal cell carcinoma"

Jump to navigation Jump to search
no edit summary
Line 12: Line 12:
| Molecular  =
| Molecular  =
| IF        =
| IF        =
| Gross      = may be multifocal, must be >0.5 cm (otherwise [[renal papillary adenoma]]), often necrotic-appearing (brown, soft, friable)
| Gross      = may be multifocal, must be >1.5 cm (otherwise [[renal papillary adenoma]]), often necrotic-appearing (brown, soft, friable)
| Grossing  = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]
| Grossing  = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]
| Staging    = [[kidney cancer staging]]
| Staging    = [[kidney cancer staging]]
Line 35: Line 35:
*Often subclassified<ref name=Ref_GUP289>{{Ref GUP|289}}</ref> into ''type 1'' and ''type 2'' -- see ''microscopic''.
*Often subclassified<ref name=Ref_GUP289>{{Ref GUP|289}}</ref> into ''type 1'' and ''type 2'' -- see ''microscopic''.
**Type 1 and Type 2 are different on a cytogenetic and molecular basis.<ref>{{Cite journal  | last1 = Klatte | first1 = T. | last2 = Pantuck | first2 = AJ. | last3 = Said | first3 = JW. | last4 = Seligson | first4 = DB. | last5 = Rao | first5 = NP. | last6 = LaRochelle | first6 = JC. | last7 = Shuch | first7 = B. | last8 = Zisman | first8 = A. | last9 = Kabbinavar | first9 = FF. | title = Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. | journal = Clin Cancer Res | volume = 15 | issue = 4 | pages = 1162-9 | month = Feb | year = 2009 | doi = 10.1158/1078-0432.CCR-08-1229 | PMID = 19228721 }}</ref>
**Type 1 and Type 2 are different on a cytogenetic and molecular basis.<ref>{{Cite journal  | last1 = Klatte | first1 = T. | last2 = Pantuck | first2 = AJ. | last3 = Said | first3 = JW. | last4 = Seligson | first4 = DB. | last5 = Rao | first5 = NP. | last6 = LaRochelle | first6 = JC. | last7 = Shuch | first7 = B. | last8 = Zisman | first8 = A. | last9 = Kabbinavar | first9 = FF. | title = Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. | journal = Clin Cancer Res | volume = 15 | issue = 4 | pages = 1162-9 | month = Feb | year = 2009 | doi = 10.1158/1078-0432.CCR-08-1229 | PMID = 19228721 }}</ref>
Note:
*The 2004 [[WHO]] GU (blue) book states that some pathologists report papillary renal cell carcinomas that are 0.5-2.0 cm as ''papillary epithelial neoplasm of low malignant potential''.<ref>{{Ref WHOGU|28}}</ref> ''Papillary epithelial neoplasm of low malignant potential'' should '''not''' be confused the similarly sounding papillary urothelial lesion (''[[papillary urothelial neoplasm of low malignant potential]]'').


===Epidemiology===
===Epidemiology===
Line 45: Line 42:


==Gross==
==Gross==
*Renal cortical mass > 0.5 cm.
*Renal cortical mass > 1.5 cm.<ref name=pmid26935559>{{Cite journal  | last1 = Moch | first1 = H. | last2 = Cubilla | first2 = AL. | last3 = Humphrey | first3 = PA. | last4 = Reuter | first4 = VE. | last5 = Ulbright | first5 = TM. | title = The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. | journal = Eur Urol | volume =  | issue =  | pages =  | month = Feb | year = 2016 | doi = 10.1016/j.eururo.2016.02.029 | PMID = 26935559 }}</ref> †
*May be multifocal. ‡
*May be multifocal. ‡
*Often necrotic appearing - light-to-dark brown, soft/mushy, friable.
*Often necrotic appearing - light-to-dark brown, soft/mushy, friable.


Note:
Note:
*† The size cut in the 2004 [[WHO]] GU (blue) book was 0.5 cm.<ref>{{Ref WHOGU|28}}</ref>
*‡ Approximately 10% of PaRCCs are multifocal (based on a set of 5378 patients);<ref name=pmid22502873>{{Cite journal  | last1 = Siracusano | first1 = S. | last2 = Novara | first2 = G. | last3 = Antonelli | first3 = A. | last4 = Artibani | first4 = W. | last5 = Bertini | first5 = R. | last6 = Carini | first6 = M. | last7 = Carmignani | first7 = G. | last8 = Ciciliato | first8 = S. | last9 = Cunico | first9 = SC. | title = Prognostic role of tumour multifocality in renal cell carcinoma. | journal = BJU Int | volume = 110 | issue = 11 Pt B | pages = E443-8 | month = Dec | year = 2012 | doi = 10.1111/j.1464-410X.2012.11121.x | PMID = 22502873 }}</ref> it is the renal tumour that is most commonly multifocal.
*‡ Approximately 10% of PaRCCs are multifocal (based on a set of 5378 patients);<ref name=pmid22502873>{{Cite journal  | last1 = Siracusano | first1 = S. | last2 = Novara | first2 = G. | last3 = Antonelli | first3 = A. | last4 = Artibani | first4 = W. | last5 = Bertini | first5 = R. | last6 = Carini | first6 = M. | last7 = Carmignani | first7 = G. | last8 = Ciciliato | first8 = S. | last9 = Cunico | first9 = SC. | title = Prognostic role of tumour multifocality in renal cell carcinoma. | journal = BJU Int | volume = 110 | issue = 11 Pt B | pages = E443-8 | month = Dec | year = 2012 | doi = 10.1111/j.1464-410X.2012.11121.x | PMID = 22502873 }}</ref> it is the renal tumour that is most commonly multifocal.


48,830

edits

Navigation menu